Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology Co's EBIT per Share for the
six
months ended in Dec. 2025 was €0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.
During the past 12 months, the average EBIT per Share Growth Rate of Medlive Technology Co was 46.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 35.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medlive Technology Co's EBIT per Share or its related term are showing as below:
FRA:1JZ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -13.3 Med: 19.8 Max: 73.9
Current: 35.1
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Medlive Technology Co was 73.90% per year. The lowest was -13.30% per year. And the median was 19.80% per year.
FRA:1JZ's 3-Year EBIT Growth Rate is ranked better than 75.91% of 523
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs FRA:1JZ: 35.10
Medlive Technology Co (FRA:1JZ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medlive Technology Co EBIT per Share Related Terms
Medlive Technology Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Medlive Technology Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co (FRA:1JZ) has a EBIT per Share of €0.06 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medlive Technology Co and its competitors. According to the industry distribution chart, Medlive Technology Co ranks #126 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 24.1%.
Is Medlive Technology Co's EBIT per Share too high?
Medlive Technology Co's current EBIT per Share is €0.06. Based on the distribution chart, Medlive Technology Co ranks #126 out of 523 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medlive Technology Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #126 out of 523 companies for EBIT per Share. This places Medlive Technology Co in the top 24% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current EBIT per Share is €0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Medlive Technology Co (FRA:1JZ) has a current EBIT per Share of €0.06. The stock's GF Value™ is €1.61, compared to a current price of €0.84 — trading 47.6% below its estimated fair value. The current EBIT per Share is €0.06. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medlive Technology Co (FRA:1JZ), the current EBIT per Share is €0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (FRA:1JZ) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of €0.84 is trading 47.6% below its estimated GF Value™ of €1.61.
Key valuation signals for FRA:1JZ:
EBIT per Share: €0.06
GF Value™: €1.61 vs. price of €0.84 (47.6% below fair value)
No single metric tells the full story. See the FRA:1JZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for FRA:1JZ
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JZ has been successfully added to your 
